Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Debt to Equity (2016 - 2018)

Historic Debt to Equity for Niagen Bioscience (NAGE) over the last 3 years, with Q4 2018 value amounting to $0.01.

  • Niagen Bioscience's Debt to Equity fell 1246.17% to $0.01 in Q4 2018 from the same period last year, while for Dec 2018 it was $0.01, marking a year-over-year decrease of 1246.17%. This contributed to the annual value of $0.01 for FY2018, which is 1246.17% down from last year.
  • Latest data reveals that Niagen Bioscience reported Debt to Equity of $0.01 as of Q4 2018, which was down 1246.17% from $0.01 recorded in Q4 2017.
  • Niagen Bioscience's 5-year Debt to Equity high stood at $0.92 for Q1 2016, and its period low was $0.01 during Q4 2018.
  • Over the past 3 years, Niagen Bioscience's median Debt to Equity value was $0.02 (recorded in 2016), while the average stood at $0.24.
  • As far as peak fluctuations go, Niagen Bioscience's Debt to Equity crashed by 9626.74% in 2016, and later tumbled by 1246.17% in 2018.
  • Niagen Bioscience's Debt to Equity (Quarter) stood at $0.03 in 2016, then crashed by 83.3% to $0.01 in 2017, then fell by 12.46% to $0.01 in 2018.
  • Its Debt to Equity was $0.01 in Q4 2018, compared to $0.01 in Q4 2017 and $0.03 in Q4 2016.